Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: The role of nitric oxide and IL-1β

Pharmacological Reports

Volumn 65, Issue 1, 2013, Pages 134-143

  Moezi, Leila ^a,b   Heidari, Reza ^a   Amirghofran, Zahra ^a   Nekooeian, Ali Akbar ^a   Monabati, Ahmad ^a   Dehpour, Ahmad R ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cirrhosis; Gastric ulcers; IL 1 ; Nitric oxide; Pioglitazone; Rat

Indexed keywords

AMINOGUANIDINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIULCER ACTIVITY; ARTICLE; BILE DUCT LIGATION; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; HISTOPATHOLOGY; LIVER CIRRHOSIS; LONG TERM CARE; MALE; NONHUMAN; RAT; STOMACH MUCOSA LESION; STOMACH PROTECTION; STOMACH ULCER; ULCER HEALING;

EID: 84875762552     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)70971-x     Document Type: Article

References (60)

1. Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, Dehpour AR: Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol, 2011, 650, 240-248.
2. Andrews FJ, Malcontenti C, O'Brien PE: Sequence of gastric mucosal injury following ischemia and reperfusion. Role of reactive oxygen metabolites. Dig Dis Sci, 1992, 37, 1356-1361.
3. Auwerx J: PPARγ, the ultimate thrifty gene. Diabetologia, 1999, 42, 1033-1049.
4. Bagi Z, Koller A, Kaley G: PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol, 2004, 286, H742-748.
5. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology, 1996, 137, 354-366.
6. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC: Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem, 2002, 82, 615-624.
7. Brzozowski T, Konturek PC, Konturek SJ, Kwiecien S, Sliwowski Z, Pajdo R, Duda A et al.: Implications of reactive oxygen species and cytokines in gastroprotection against stress-induced gastric damage by nitric oxide releasing aspirin. Int J Colorectal Dis, 2003, 18, 320-329.
8. Brzozowski T, Konturek PC, Pajdo R, Kwiecien SN, Konturek S, Targosz A, Burnat G et al.: Agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ): a new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology, 2005, 13, 317-330.
9. Cameron GR, Oakley, C.L.: Ligation of common bile duct. J Pathol Bacteriol, 1932, 35, 769-798.
10. Chamoun F, Burne M, O'Donnell M, Rabb H: Pathophysiologic role of selectins and their ligands in ischemia reperfusion injury. Front Biosci, 2000, 5, E103-109.
11. Chen LS, Lin HC, Hwang SJ, Lee FY, Hou MC, Lee SD: Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. J Gastroenterol Hepatol, 1996, 11, 59-64.
12. Chen LS, Lin HC, Lee FY, Hou MC, Lee SD: Prevalence of duodenal ulcer in cirrhotic patients and its relation to Helicobacter pylori and portal hypertension. Zhonghua Yi Xue Za Zhi (Taipei), 1995, 56, 226-231.
13. Farzaneh-Far R, Moore K: Nitric oxide and the liver. Liver, 2001, 21, 161-174.
14. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE et al.: Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol, 2002, 51, 694-702.
15. Floyd JS, Barbehenn E, Lurie P,Wolfe SM: Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf, 2009, 18, 1238-1243.
16. Fujiwara Y, Arakawa T, Higuchi K, Kuroki T: Gastrointestinal lesions in liver cirrhosis (Japanese). Nippon Rinsho, 1998, 56, 2387-2390.
17. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, Vilardell F et al.: Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology, 1993, 18, 1139-1143.
18. Gyires K: The role of endogenous nitric oxide in the gastroprotective action of morphine. Eur J Pharmacol, 1994, 255, 33-37.
19. Hara N, Hara Y, Natsume Y, Goto Y: Gastric hyperacidity and mucosal damage caused by hypothermia correlate with increase in GABA concentrations of the rat brain. Eur J Pharmacol, 1991, 194, 77-81.
20. Heneka MT, Klockgether T, Feinstein DL: Peroxisome proliferator-activated receptor-g ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci, 2000, 20, 6862-6867.
21. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K et al.: Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453.
22. Jiang C, Ting AT, Seed B: PPAR-g agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391, 82-86.
23. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K: Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun, 2004, 315, 187-195.
24. Kirk AP, Dooley JS, Hunt RH: Peptic ulceration in patients with chronic liver disease. Dig Dis Sci, 1980, 25, 756-760.
25. Kitamura Y, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T: Activators of peroxisome proliferator-activated receptor-γ (PPARγ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett, 1999, 262, 129-132.
26. Kitano S, Dolgor B: Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis? J Gastroenterol, 2000, 35, 79-86.
27. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N: Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride . Biochem Biophys Res Commun, 2002, 291, 55-61.
28. Konturek PC, Brzozowski T, Kania J, Konturek SJ, Kwiecien S, Pajdo R, Hahn EG: Pioglitazone, a specific ligand of peroxisome proliferator-activated receptorgamma, accelerates gastric ulcer healing in rat. Eur J Pharmacol, 2003, 472, 213-220.
29. Konturek PC, Brzozowski T, Kania J, Kukharsky V, Bazela K, Kwiecien S, Harsch I et al.: Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/reperfusion in rat. Scand J Gastroenterol, 2003, 38, 468-476.
30. Lahiri S, Sen T, Palit G: Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-γ in pioglitazone mediated chronic gastric ulcer healing in rats. Eur J Pharmacol, 2009, 609, 118-125.
31. Lee FY, Wang SS, Tsai YT, Lin HJ, Lin HC, Chu CJ, Wu SL et al.: Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol, 1997, 26, 687-693.
32. McIntyre RS, Soczynska JK, Lewis GF, MacQueen GM, Konarski JZ, Kennedy SH: Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother, 2006, 7, 1305-1321.
33. Miller TA, Henagan JM: Indomethacin decreases resistance of gastric barrier to disruption by alcohol. Dig Dis Sci, 1984, 29, 141-149.
34. Nakamura E, Takahashi S, Ishikawa M, Okabe S: Inhibitory effect of macrophage-derived factors on the recovery of wounds induced in rat gastric epithelial monolayers. Biochem Pharmacol, 1999, 58, 1221-1227.
35. Okada M, Yan SF, Pinsky DJ: Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J, 2002, 16, 1861-1868.
36. Pereira MP, Hurtado O, Cárdenas A, Bosca L, Castillo J, Dávalos A, Vivancos J et al.: Rosiglitazone and 15-deoxy-Δ12,14- prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab, 2006, 26, 218-229.
37. Polat B, Albayrak Y, Suleyman B, Dursun H, Odabasoglu F, Yigiter M, Halici Z et al.: Antiulcerative effect of dexmedetomidine on indomethacin-induced gastric ulcer in rats. Pharmacol Rep, 2011, 63, 518-526.
38. Rabinovitz M, Schade RR, Dindzans V, Van Thiel DH, Gavaler JS: Prevalence of duodenal ulcer in cirrhotic males referred for liver transplantation. Does the etiology of cirrhosis make a difference? Dig Dis Sci, 1990, 35, 321-326.
39. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 1998, 391, 79-82.
40. Robert A: Cytoprotection by prostaglandins. Gastroenterology, 1979, 77, 761-767.
41. Sacchetti C, Capello M, Rebecchi P, Roncucci L, Zanghieri G, Tripodi A, Ponz de Leon M: Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. Dig Dis Sci, 1988, 33, 1218-1222.
42. Sato T, Asanuma Y, Masaki Y, Sato Y, Hatakeyama Y, Kusano T, Koyama K: Changes in tumor necrosis factor-α and interleukin-1β production following liver surgery on cirrhotic patients. Hepatogastroenterology, 1996, 43, 1148-1153.
43. Saxena B, Singh S: Investigations on gastroprotective effect of citalopram, an antidepressant drug against stress and pyloric ligation induced ulcers. Pharmacol Rep, 2011, 63, 1413-1426.
44. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR: PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci, 2009, 29, 954-963.
45. Siringo S, Burroughs AK, Bolondi L, Muia A, Di Febo G, Miglioli M, Cavalli Barbara L: Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. J Hepatol, 1995, 22, 633-641.
46. Siringo S, Vaira D, Menegatti M, Piscaglia F, Sofia S, Gaetani M, Miglioli M et al.: High prevalence of Helico-bacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. Dig Dis Sci, 1997, 42, 2024-2030.
47. Slomiany BL, Slomiany A: Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor γ activation. IUBMB Life, 2002, 53, 303-308.
48. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A et al.: A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest, 1999, 104, 383-389.
49. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE: Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience, 2005, 130, 685-696.
50. Szabo S, Trier JS, Frankel PW: Sulfhydryl compounds may mediate gastric cytoprotection. Science, 1981, 214, 200-202.
51. Takahashi S, Fujita T, Yamamoto A: Role of nuclear factor-κB in gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol, 2001, 280, G1296-1304.
52. Tazi KA, Barriere E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D: Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology, 2002, 122, 1869-1877.
53. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C: Serum levels of cytokines in chronic liver diseases. Gastroenterology, 1992, 103, 264-274.
54. Tolman KG, Freston JW, Kupfer S, Perez A: Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf, 2009, 32, 787-800.
55. Tsai CJ: Helicobacter pylori infection and peptic ulcer disease in cirrhosis. Dig Dis Sci, 1998, 43, 1219-1225.
56. Vallance P, Moncada S: Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet, 1991, 337, 776-778.
57. Witt CG, Will PC, Gaginella TS: Quantification of ethanol-induced gastric mucosal injury by transmission densitometry. J Pharmacol Methods, 1985, 13, 109-116.
58. Wu CS, Lin CY, Liaw YF: Helicobacter pylori in cirrhotic patients with peptic ulcer disease: a prospective, case controlled study. Gastrointest Endosc, 1995, 42, 424-427.
59. Xu L, Carter EP, Ohara M, Martin PY, Rogachev B, Morris K, Cadnapaphornchai M et al.: Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol Renal Physiol, 2000, 279, F1110-1115.
60. Yuan GJ, Zhang ML, Gong ZJ: Effects of PPARγ agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol, 2004, 10, 1047-1051.